MyD88 signalling is critical in the development of pancreatic cancer cachexia.

ABSTRACT:

Background

Up to 80% of pancreatic cancer patients suffer from cachexia, a devastating condition that exacerbates underlying disease, reduces quality of life, and increases treatment complications and mortality. Tumour-induced inflammation is linked to this multifactorial wasting syndrome, but mechanisms and effective treatments remain elusive. Myeloid differentiation factor (MyD88), a key component of the innate immune system, plays a pivotal role in directing the inflammatory response to various insults. In this study, we tested whether MyD88 signalling is essential in the development of pancreatic cancer cachexia using a robust mouse tumour model.

Methods

Sex, age, and body weight-matched wide type (WT) and MyD88 knockout (MyD88 KO) mice were orthotopically or intraperito

SUBMITTER: Zhu X 

PROVIDER: S-EPMC6463469 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature